This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron, and a pivotal court decision clearing the ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short of market expectations.